51st Annual Meeting & ToxExpo - Society of Toxicology

Society of Toxicology 2012
Scientific
Workshops
The Thematic Track information can be found on pages 8–9.
• Effects of Immunosuppressive Drugs in Preclinical Models of
Neoplasia. Mindi Walker, Centocor, Radnor, PA.
• Immunomodulation and Cancer: Risk Assessment and Weight of
Evidence Evaluations. Helen Haggerty, Bristol-Myers Squibb, New
Brunswick, NJ.
• Immunomodulation and Cancer: A Regulatory Perspective.
Dan Mellon, US FDA, Silver Spring, MD.
Regulatory Science: Bridging the
Gap between Discovery and Product
Availability
Concepts Critical to the Next Generation of
Human Health and Ecological Risk Assessment
Monday, March 12, 2:00 PM to 4:45 PM
Chairperson(s): P. Robinan Gentry, ENVIRON Interntational
Corporation, Monroe, LA, and Betty Locey, ARCADIS, Ann Arbor,
MI.
Sponsor:
Risk Assessment Specialty Section
Through the collaborative effort between the SOT Risk Assessment
Specialty Section and the SETAC Human Health Risk Assessment
Advisory Group, this session was developed to highlight the challenges
currently facing the next generation of risk assessors. With the
release of the recent National Academy of Sciences reports on toxicity
testing that present a vision for movement from in vivo testing to
in vitro and in silico testing, as well as the most recent changes in risk
assessment guidelines by regulatory agencies, risk assessors are faced
with the challenge of integrating innovative data (e.g., genomics) into
the current risk assessment paradigms or with the development of new
paradigms or methods to address changing issues in risk assessment.
In considering all the biological changes and scientific information,
many of these new methods attempt to integrate all of the available
scientific information of a compound to better inform both human
health and ecological risk assessment/risk management decisions.
Our panel of experts will provide information on new programs and
approaches within regulatory agencies, as well as in the private sector,
that will be important in the next generation of risk assessment.
• A More Efficient and Effective Testing and Assessment Paradigm
for Chemical Risk Management. Steven Bradbury, US EPA,
Washington, DC.
• MABEL: Use of Preclinical Data to Set Acceptable Standards for
Exposure. Gretchen Bruce, Intertox, Inc., Seattle, WA.
• Using Transcriptomic Data in the Risk Assessment Paradigm.
Russell S.Thomas, The Hamner Institutes for Health Sciences,
Research Triangle Park, NC.
• Adverse Outcome Pathways As a Unifying Concept in
Environmental Toxicology. Kevin Crofton, US EPA,
Research Triangle Park, NC.
• Mixtures Risk Management: Moving beyond TEQs and Hazard
Indices. Paul Price, Dow Chemical Company, Midland, MI.
Tuesday
Assessing the Bioavailability and Risk from Metal-
Contaminated Soils and Dusts
Tuesday, March 13, 9:00 AM to 11:45 AM
Chairperson(s): Michael Hughes, US EPA, Research Triangle Park,
NC, and Karen Bradham, US EPA, Research Triangle Park, NC.
Sponsor:
Metals Specialty Section
Endorsed by:
Occupational and Public Health Specialty Section
Exposure to contaminated soil and dust is an important pathway in
human and ecological risk assessment and often is the risk-driver for
metal-contaminated soil. Site-specific soil physical and chemical characteristics,
as well as biological factors, determine the bioavailability
of soil contaminants. Within a single sample, contamination may be
from multiple sources of toxic elements that may exist as different
forms and species. The bioavailability of soil and dust contaminants
has a direct impact on human health risk assessment and risk
management practices. Novel research efforts focusing on development
and application of in vitro and in vivo methods to measure the
bioavailability of metal-contaminated soils have advanced in the past
few years. Our panel of experts will provide information on the recent
developments in assessing the bioavailability and risk from metalcontaminated
soils and dusts. The presentations include the relative
bioavailability of arsenic-contaminated soils, metal contamination
in urban residences in Canada, and potential children’s exposures
to toxic elements in house dust. The information can be found in a
community-based study known as the “West Oakland Residential
Lead Assessment Study,” which provides details of the bioavailability
of soil cadmium, chromium, nickel, and mercury, and human
exposures to contaminated Brownfield soils. These presentations
cover issues related to human health and bioavailability along with
the most recent studies on community participation in assessing
metal contamination, studies of children’s exposures to residential
contamination, and recent in vitro and in vivo methods development
for assessing the bioavailability of metals in soils and dusts. This
session seeks to provide a forum for discussing the implications of
these latest developments on incorporating bioavailability into the
risk assessment and management process.
Thematic Session
88
SOT’s 51 st Annual Meeting